Clinical Trial Update: Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated the safety and immune response of two serogroup B meningococcal vaccines in healthy adolescents; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Meningococcal B vaccine candidate 1
• Meningococcal B vaccine candidate 2

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Disease | Phase 2 | Status: COMPLETED